PSS9 - A Cost-Per-Responder Analysis of Secukinumab Compared with Ustekinumab in Saudi Arabia: Results from the Clear Study of Patients With Moderate to Severe Psoriasis

Journal article

Open access

Peer reviewed

M Al Howimel, K Al Jufan, A AlAlwan, N Alshehri, H Al Mudaiheem, A Al Amri, H Al Hamdan, N Zakaria, L Al Kateb, I Gilloteau, …

Value in health, Vol.21, pp.S106-S106

09/2018

Files and links (1)

url

https://doi.org/10.1016/j.jval.2018.07.808View

Published (Version of record) Open

1 Record Views

Title: PSS9 - A Cost-Per-Responder Analysis of Secukinumab Compared with Ustekinumab in Saudi Arabia: Results from the Clear Study of Patients With Moderate to Severe Psoriasis
Creators - without role: M Al Howimel - National Guard Health Affairs
K Al Jufan - National Guard Health Affairs
A AlAlwan - Riyadh Armed Forces Hospital
N Alshehri - Riyadh Armed Forces Hospital
H Al Mudaiheem - Ministry of Health
A Al Amri - National Guard Health Affairs
H Al Hamdan - National Guard Health Affairs
N Zakaria - Novartis, Riyadh, Saudi Arabia
L Al Kateb - Novartis, Riyadh, Saudi Arabia
I Gilloteau - Novartis
C N Graham - RTI Health Solutions
M Sekharan - Novartis
Publication Details: Value in health, Vol.21, pp.S106-S106
Publisher: Elsevier Inc
Identifiers: 9920893908331
Academic Unit: King Saud University
Language: English
Resource Type: Journal article